TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

ANZEMET

DOLASETRON MESYLATE
Approved 1997-09-11
1
Indication
--
Phase 3 Trials
28
Years on Market

Details

Status
Discontinued
First Approved
1997-09-11
Routes
ORAL, INJECTION
Dosage Forms
TABLET, INJECTABLE

Companies

Active Ingredient: DOLASETRON MESYLATE

ANZEMET Approval History

Loading approval history...

What ANZEMET Treats

1 FDA approvals

Originally approved for its first indication in 1997 .

  • Other (1)
๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

ANZEMET FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.